Hot, Not & Doing: R8R, NIM, OD6, AT4, NVU, PL9, SRZ & GRL
What’s Hot – R8R, NIM, OD6, AT4, NVU, PL9, SRZ & GRL What’s Hot R8R – Regener8 Resources Limited today closed up 73% to finish at 19c on $240k stock traded. The reason they were up today was because they announced the acquisition of the Srebrenica North Silver-Copper-Antimony-Zinc-Lead Project located in Bosnia & Herzegovina. NIM […]
Electro Optic Systems (ASX:EOS): Transformation driving global defence and space growth in 2026
Transcription of The Stock Network Interview with Electro Optic Systems (ASX:EOS), Dr Andreas Schwer, Managing Director and CEO Lel Smits: Electro-Optic Systems has completed a multi-year transformation, strengthening leadership, commercializing high-energy laser and space control IP, and expanding into growth markets while also enhancing its counter-drone portfolio. With an unconditional backlog of $459.1 million, EOS […]
Hot, Not & Doing: OD6, BAS, EDE, IMU, ILA & SRL
What’s Hot – OD6, BAS, EDE, IMU, ILA & SRL What’s Not – AVL What’s Hot OD6 – OD6 Metals Limited today closed up 69% to finish at 9.1c on $5m stock traded. The reason they were up today was because they announced the acquisition of a district scale cluster of historic high-grade fluorspar (CaF2) […]
Axel REE (ASX:AXL): Strong recoveries, growing resources & low-cost development plan in Brazil
Transcription of The Stock Network Interview with Axel REE (ASX:AXL), Non-Executive Chairman, Paul Dickson Lel Smits: Axel Ree is advancing its wholly owned rare earth projects in Minas Gerais in Brazil, led by the district-scale Caladao project. Recent test work confirmed very high-grade rare earth recoveries, while ongoing drilling has rapidly grown the project’s resource […]
Hot, Not & Doing: FBR, LIN, MFG, COD & VTM
What’s Hot – FBR, LIN, MFG, COD & VTM What’s Not – MGT What’s Hot FBR – FBR Limited today closed up 25% to finish at 0.5c on $200k stock traded. The reason they were up today was because they announced a binding wall as a service (WaaS) offtake agreement was executed with EW Distribution […]
Bell Financial Group (ASX:BFG): Diversified wealth strategy gains traction as platforms drive growth
Transcription of The Stock Network Interview with Bell Financial Group (ASX:BFG), Co-Chief Executive Officer Arnie Selvarajah Lel Smits: Bell Financial Group has delivered a strong full-year result, underscoring the benefits of its evolution from a traditional stockbroking house into a more diversified wealth management business. The group’s newly structured markets and platforms divisions highlight this […]
Hot, Not & Doing: SDI, BSA, CTN, RCR, VKA, MNB, MKR, SMS & BTM
What’s Hot – SDI, BSA, CTN, RCR, VKA, MNB, MKR, SMS & BTM What’s Not – 3DP What’s Hot SDI – SDI Limited today closed up 45% to finish at $1.285 on $1.8m stock traded. The reason they were up today was because back on Friday after market they announced a scheme implementation deed (SID) […]
Far East Gold (ASX:FEG): High-grade gold growth in Indonesia & emerging copper potential in QLD
Transcription of The Stock Network Interview with Far East Gold (ASX:FEG), Managing Director and CEO Shane Menere Lel Smits: Far East Gold is advancing a quality portfolio of six copper and gold projects across Indonesia and Australia. During the quarter, the company delivered high-grade drilling results at the Eidenberg project, expanded mineralisation zones at Sewer […]
Hot, Not & Doing: HFY, LSR, VKA, SMM, DTR, AWJ, SRZ & MM8
What’s Hot – HFY, LSR, VKA, SMM, DTR, AWJ, SRZ & MM8 What’s Hot HFY – Hubify Limited today closed up 163% to finish at 2.1c on $3m stock traded. The reason they were up today was because they released its half yearly results which highlighted a 84% increase in EBITDA to $330k on the […]
Arovella Therapeutics (ASX:ALA): FDA clears IND for next-gen iNKT therapy
Transcription of The Stock Network Interview with Arovella Therapeutics (ASX:ALA), CEO and Managing Director Dr Michael Baker Lel Smits: Arovella Therapeutics is a biotechnology company developing invariant natural killer T-cell therapies for the treatment of blood cancers and solid tumors. In January this year Arovella achieved a major regulatory milestone with the US FDA acceptance […]